We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.
- Authors
Wolpin, Brian M; Hezel, Aram F; Abrams, Thomas; Blaszkowsky, Lawrence S; Meyerhardt, Jeffrey A; Chan, Jennifer A; Enzinger, Peter C; Allen, Brittany; Clark, Jeffrey W; Ryan, David P; Fuchs, Charles S
- Abstract
The PI3K/Akt/mTOR pathway is activated in the majority of pancreatic cancers, and inhibition of this pathway has antitumor effects in preclinical studies. We performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), an oral inhibitor of mTOR, in patients who experienced treatment failure on first-line therapy with gemcitabine.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 2, p193
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.18.9514